Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Assets: 2013-2024

Historic Current Assets for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $534.1 million.

  • Amphastar Pharmaceuticals' Current Assets rose 17.13% to $639.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $639.5 million, marking a year-over-year increase of 17.13%. This contributed to the annual value of $534.1 million for FY2024, which is 9.08% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Current Assets stood at $534.1 million for FY2024, which was up 9.08% from $489.6 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Current Assets ranged from a high of $534.1 million in FY2024 and a low of $279.7 million during FY2020.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Current Assets value was $489.6 million (recorded in 2023), while the average stood at $467.3 million.
  • Data for Amphastar Pharmaceuticals' Current Assets shows a peak YoY increased of 29.41% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Current Assets stood at $279.7 million in 2020, then increased by 13.74% to $318.1 million in 2021, then grew by 18.92% to $378.3 million in 2022, then climbed by 29.41% to $489.6 million in 2023, then climbed by 9.08% to $534.1 million in 2024.